Tocilizumab, a Humanized Monoclonal Antibody Against the Interleukin-6 Receptor, Inhibits High Glucose-Induced Vascular Smooth Muscle Cell Migration Through Mitogen-Activated Protein Kinase Signaling Pathways

doi:10.1089/jir.2018.0009

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 高齡福祉養生管理系 > 期刊論文 > Item 310902800/32232

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/32232

標題:	Tocilizumab, a Humanized Monoclonal Antibody Against the Interleukin-6 Receptor, Inhibits High Glucose-Induced Vascular Smooth Muscle Cell Migration Through Mitogen-Activated Protein Kinase Signaling Pathways
作者:	Wu, Tao-Cheng Chiang, Chih-Yao Chan, Jenq-Shyong Lee, Chiu-Yang Leu, Hsin-Bang Huang, Po-Hsun Chen, Jia-Shiong Lin, Shing-Jong Chen, Jaw-Wen
貢獻者:	Natl Yang Ming Univ, Cardiovasc Res Ctr Taipei Vet Gen Hosp, Div Cardiol, Dept Med Taipei City Hosp, Div Cardiovasc Surg Armed Forces Tao Yuan Gen Hosp, Div Nephrol Taipei Vet Gen Hosp, Div Cardiovasc Surg, Dept Surg Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management Taipei Vet Gen Hosp, Hlth Care & Serv Ctr Taipei Vet Gen Hosp, Dept Med Res & Educ Natl Yang Ming Univ, Inst Pharmacol, Inst Clin Med, Sch Med
關鍵字:	tocilizumab human aortic smooth muscle cells interleukin-6 receptor glucose diabetes
日期:	2018-11-01
上傳時間:	2019-11-15 15:46:05 (UTC+8)
出版者:	MARY ANN LIEBERT, INC
摘要:	Rheumatoid arthritis (RA) with diabetes increases the risk of cardiovascular diseases. Interleukin-6 (IL-6) promotes the disease activity of RA and insulin resistance. This study aimed to evaluate the potential effects and molecular mechanisms of IL-6 blocker, tocilizumab, in atherosclerosis with diabetes. Human aortic smooth muscle cells (HASMCs) cultured under hyperglycemic conditions were evaluated for migration, expression of adhesion molecules, and matrix metalloproteinases before and after treatment with tocilizumab. High glucose (HG) significantly increased expression of IL-6, intercellular adhesion molecule (ICAM-1), matrix metalloproteinase-2 & 9, and migration of vascular smooth muscle cells. Tocilizumab suppressed HG-induced expression of ICAM-1, MMP-2, and MMP-9. Pretreatment with tocilizumab also inhibited migration, MAPK signaling, and nuclear translocation of p65-NF-kappa B in HG-stimulated HASMCs. Our data suggested that tocilizumab may exert an antiatherosclerotic activity in diabetes.
link:	http://dx.doi.org/10.1089/jir.2018.0009
關聯:	Cancers, v.38, n.11, pp.510-516
Appears in Collections:	[高齡福祉養生管理系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1778	View/Open

Loading...